BCL11B targeting in tumor CD8+ T cells amplifies anti-tumor response by blocking exhaustion while promoting stemness and cytotoxicity
Silvane, L.; Zelenka, T.; Talada, D. P.; Cismasiu, V. B.; Islam, S.; Singh, R. P.; Ngove, Z.; Chakraborty, S.; Hall, M. S.; Blauvelt, J. L.; Eksioglu, E.; Manrique, S. Z.; Johnson, J. O.; Obermayer, A. N.; Alfaro, A.; Huang, W.; Sarnaik, A.; Tarhini, A. A.; Mullinax, J. E.; George, E.; Hwu, P.; Davila, E.; Conejo-Garcia, J. R.; Bryceson, Y. T.; Chen, D.-T.; Shaw, T. I.; Pilon-Thomas, S.; Avram, D.
Show abstract
Tumor infiltrating CD8+ T cells (TILs) progress to a state of terminal exhaustion (Ttex) which have impaired functionality and are nonrenewable. However their precursors (Tpex) are renewable and can generate efficient effector cells. We started from the observation that melanoma patients undergoing therapy with checkpoint inhibitors show increased survival when their T cells have low BCL11B mRNA. In line with this, ablation of Bcl11b in CD8+ TILs conferred a superior anti-tumor response in murine melanoma and ovarian cancer models. Bcl11b KO TILs failed to progress to the Ttex state and retained elevated stemness. Bcl11b exerted its role by repressing expression of essential transcription factors (TF) controlling stemness, and conversely by promoting expression of exhaustion-associated TFs and inhibitory receptor genes, through complex epigenetic control. In addition, Bcl11b KO CD8+ T cells showed increased Ag-specific cytolytic activity and elevated Gzmb and Prf1 proteins, but no increase in their mRNAs, however presented higher expression of genes with role in translation. Furthermore, CRISPR-CAS9-mediated deletion of BCL11B in human TILs from a patient with poor response to adoptive cell therapy with autologous TILs, improved their cytolytic activity and promoted expression of the stemness-associated TF TCF1, underlying its potential therapeutic use. HIGHLIGHTS- Adoptive transfer of Bcl11b KO CD8+ TILs surpasses WT in tumor burden reduction - Bcl11b ablation reprograms TILs and impairs the progression to Ttex state - Bcl11b KO CD8+ T cells have elevated cytotoxicity and kill only Ag-MHCI targets - BCL11B deletion in nonresponder ACT-TIL improves cytolytic activity and elevates TCF1 GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=64 SRC="FIGDIR/small/742578v1_ufig1.gif" ALT="Figure 1"> View larger version (33K): org.highwire.dtl.DTLVardef@10040d4org.highwire.dtl.DTLVardef@1a045caorg.highwire.dtl.DTLVardef@145f790org.highwire.dtl.DTLVardef@8012ab_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Stem-like PD-1+TCF-1+ CD8+ T cells result from helpless priming and rely on CD4+ T-cell help to complete their cytotoxic effector differentiation 94%
- Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis 93%
- TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant 93%
Similar papers in this journal
- Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: Insights from in vitro assays 94%
- Augmented expansion of Treg cells from healthy and autoimmune subjects via adult progenitor cell co-culture. 93%
- A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma 92%
Similar papers in this journal
- Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses 92%
- Single-cell clonal lineage tracing identifies the transcriptional program controlling the cell fate decisions by neoantigen-specific CD8+ T cells 92%
- Small gene networks can delineate immune cell states and characterize immunotherapy response in melanoma 91%
Similar papers in this journal
- Metabolic reinvigoration of NK cells by IL-21 enhances immunotherapy against MHC-I deficient solid tumors 94%
- Single-cell profiling of tumor-reactive CD4+ T-cells reveals unexpected transcriptomic diversity 92%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 92%
Similar papers in this journal
- Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors 92%
- Pinpointing the tumor-specific T-cells via TCR clusters 91%
- Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.